Keywords:
Breast, MR-Diffusion/Perfusion, Diagnostic procedure
Authors:
A. SPEZZACATENE, M. TONUTTI, F. GIUDICI, F. Zanconati, M. A. Cova; Trieste/IT
DOI:
10.26044/ecr2019/C-2197
Methods and materials
In this study,
we included 46 women (mean age 58 ±11 years) with 53 MRI-detected breast lesions who underwent 3T breast MRI from September 2017 to September 2018 at Radiology Department,
Azienda Sanitaria Universitaria Integrata di Trieste,
Trieste,
Italy.
MRI-detected breast lesions were those characterized as Breast Imaging Reporting and Data System (BI-RADS) category 3,
4 or 5 [7] with subsequent benign or malignant confirmation (cytologic or histologic examination or benign finding,
BI-RADS U2,
at II level ultrasound).
We excluded from the analysis known malignant breast lesions (BI-RADS 6),
lesions without cyto/histologic confirmation,
lesions that were not detectable at II level ultrasound and subjects receiving neoadjuvant chemotherapy <6 months prior to the MRI.
Clinical indication for breast MRI included the staging of known cancer,
high-risk screening and problem-solving (in case of any radiologic and/or cyto-histologic discrepancy).
Breast MRI was performed with a Philips Ingenia 3T MRI scanner with dedicated multichannel bilateral breast coil.
MRI sequences were obtained in the axial orientation and each MRI exam included Turbo spin-echo DIXON T2-weighted sequences,
DWI sequences (b values: 50-850 mm2/s) [6] and T1-weighted fat-suppressed DCE MRI sequences with one precontrast and five postcontrast acquisitions.
Post-processing analysis was performed with dedicated software (IntelliSpace Portal 9.0,
Philips).
Statistical analysis was performed with R software version 3.5.0 (The R Foundation for Statistical Computing) and STATA software version 14.2 (StataCorp,
College Station,
Texas).